Ante Jelaska

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

Julio Rosenstock, Ante Jelaska, Guillaume Frappin et al. · Diabetes Care · 2014 · 358 citations

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

Julio Rosenstock, Ante Jelaska, Cordula Zeller et al. · Diabetes Obesity and Metabolism · 2015 · 252 citations · Full text

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska et al. · Diabetes Obesity and Metabolism · 2013 · 208 citations

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

Juan C. Salazar, Pedro Cahn, Ram Yogev et al. · AIDS · 2008 · 40 citations · Full text

Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)

Julio Rosenstock, Ante Jelaska, Fei Wang et al. · Canadian Journal of Diabetes · 2013 · 38 citations

Obesity, Metabolic Syndrome, Diabetes Management +11